147 related articles for article (PubMed ID: 37934348)
1. Gastric cancer with Fanconi anemia in adolescent and young adult patient diagnosed by comprehensive genome profiling using next-generation sequencing.
Namikawa T; Tanaka T; Utsunomiya M; Yokota K; Munekage M; Maeda H; Kitagawa H; Kurioka Y; Satake H; Kobayashi M; Hanazaki K; Seo S
Clin J Gastroenterol; 2024 Feb; 17(1):12-17. PubMed ID: 37934348
[TBL] [Abstract][Full Text] [Related]
2. [Long-Term Survival of an Adolescent and Young Adult Patient with Unresectable Advanced Gastric Cancer in Whom Multidisciplinary Treatment Was Effective].
Namikawa T; Utsunomiya M; Yokota K; Kawanishi Y; Yamaguchi S; Munekage M; Maeda H; Kitagawa H; Nagata Y; Kobayashi M; Hanazaki K; Seo S
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1985-1987. PubMed ID: 38303273
[TBL] [Abstract][Full Text] [Related]
3. Successful Conversion Surgery for Advanced Gastric Cancer With Multiple Liver Metastases Following Ramucirumab Plus Paclitaxel Combination Treatment.
Namikawa T; Marui A; Yokota K; Fujieda Y; Munekage M; Uemura S; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
In Vivo; 2021; 35(5):2929-2935. PubMed ID: 34410989
[TBL] [Abstract][Full Text] [Related]
4. Treatment with Ramucirumab-paclitaxel in a metastatic gastric cancer patient undergoing hemodialysis: A case report.
Yang MJ; Choi YJ; Kim HJ; Kim DY; Seol YM
Medicine (Baltimore); 2021 Feb; 100(7):e24795. PubMed ID: 33607838
[TBL] [Abstract][Full Text] [Related]
5. Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial.
Yoshikawa T; Muro K; Shitara K; Oh DY; Kang YK; Chung HC; Kudo T; Chin K; Kadowaki S; Hamamoto Y; Hironaka S; Yoshida K; Yen CJ; Omuro Y; Bai LY; Maeda K; Ozeki A; Yoshikawa R; Kitagawa Y
JAMA Netw Open; 2019 Aug; 2(8):e198243. PubMed ID: 31373648
[TBL] [Abstract][Full Text] [Related]
6. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Chemotherapy Following Anti-PD-1 Antibody Therapy for Gastric Cancer: A Case of Sclerosing Cholangitis.
Kono M; Sakurai T; Okamoto K; Masaki S; Nagai T; Komeda Y; Kamata K; Minaga K; Yamao K; Takenaka M; Watanabe T; Nishida N; Kudo M
Intern Med; 2019 May; 58(9):1263-1266. PubMed ID: 30626829
[TBL] [Abstract][Full Text] [Related]
8. Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis.
Ishikawa M; Iwasa S; Nagashima K; Aoki M; Imazeki H; Hirano H; Shoji H; Honma Y; Okita N; Takashima A; Kato K; Saruta M; Boku N
Invest New Drugs; 2020 Apr; 38(2):533-540. PubMed ID: 31264067
[TBL] [Abstract][Full Text] [Related]
9. Conversion surgery for stage IV gastric cancer with a complete pathological response to nivolumab: a case report.
Matsumoto R; Arigami T; Matsushita D; Okubo K; Tanaka T; Yanagita S; Sasaki K; Noda M; Kita Y; Mori S; Kurahara H; Ohtsuka T
World J Surg Oncol; 2020 Jul; 18(1):179. PubMed ID: 32693806
[TBL] [Abstract][Full Text] [Related]
10. [A Case of Perforation of the Diverticulum of the Appendix during Chemotherapy with Ramucirumab plus Nab-Paclitaxel for Gastric Cancer].
Kurihara M; Sawazaki S; Kawabe T; Minowa K; Akimoto N; Tsuchiya K; Kato A; Higuchi A; Rino Y; Matsukawa H; Saeki H
Gan To Kagaku Ryoho; 2021 Oct; 48(10):1293-1295. PubMed ID: 34657068
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
Bando H; Shimodaira H; Fujitani K; Takashima A; Yamaguchi K; Nakayama N; Takahashi T; Oki E; Azuma M; Nishina T; Hironaka S; Komatsu Y; Shitara K
Eur J Cancer; 2018 Mar; 91():86-91. PubMed ID: 29353164
[TBL] [Abstract][Full Text] [Related]
12. [A Case Report of Inoperable Gastric Cancer with Peritoneal Dissemination, Liver Metastasis, and Lung Metastasis Successfully Treated with Weekly Paclitaxel and Ramucirumab].
Takahashi S; Hanaka J; Takahashi M; Goya T
Gan To Kagaku Ryoho; 2019 Jun; 46(6):1065-1067. PubMed ID: 31273177
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial.
Xu RH; Zhang Y; Pan H; Feng J; Zhang T; Liu T; Qin Y; Qin S; Yin X; Liu B; Ba Y; Yang N; Voon PJ; Tanasanvimon S; Zhou C; Zhang WL; Shen L
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1015-1024. PubMed ID: 34626550
[TBL] [Abstract][Full Text] [Related]
14. Ureteral rupture with retroperitoneal urinoma caused by peritoneal metastases of gastric cancer.
Namikawa T; Yokota K; Munekage M; Uemura S; Maeda H; Kitagawa H; Tamura T; Karashima T; Inoue K; Kobayashi M; Hanazaki K
Int Cancer Conf J; 2023 Jan; 12(1):53-58. PubMed ID: 36605840
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial.
Kim ST; Sa JK; Oh SY; Kim K; Hong JY; Kang WK; Kim KM; Lee J
Genome Med; 2021 Jan; 13(1):11. PubMed ID: 33494793
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol.
Cheng X; Wu D; Xu N; Chen L; Yan Z; Chen P; Zhou L; Yu J; Cui J; Li W; Wang C; Feng W; Wei Y; Yu P; Du Y; Ying J; Xu Z; Yang L; Zhang Y
BMC Cancer; 2021 Jan; 21(1):56. PubMed ID: 33435909
[TBL] [Abstract][Full Text] [Related]
17. [Brain Metastasis Arising from Gastric Cancer during Long-Term Treatment Using Nivolumab].
Namikawa T; Marui A; Yokota K; Kawanishi Y; Munekage M; Uemura S; Maeda H; Kitagawa H; Nagata Y; Kobayashi M; Hanazaki K
Gan To Kagaku Ryoho; 2022 Dec; 49(13):1544-1546. PubMed ID: 36733129
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.
Di Bartolomeo M; Niger M; Morano F; Corallo S; Antista M; Tamberi S; Lonardi S; Di Donato S; Berardi R; Scartozzi M; Cardellino GG; Di Costanzo F; Rimassa L; Luporini AG; Longarini R; Zaniboni A; Bertolini A; Tomasello G; Pinotti G; Scagliotti G; Tortora G; Bonetti A; Spallanzani A; Frassineti GL; Tassinari D; Giuliani F; Cinieri S; Maiello E; Verusio C; Bracarda S; Catalano V; Basso M; Ciuffreda L; De Vita F; Parra HS; Fornaro L; Caporale M; de Braud F; Pietrantonio F
BMC Cancer; 2019 Mar; 19(1):283. PubMed ID: 30922323
[TBL] [Abstract][Full Text] [Related]
19. [Salvage Surgery for Unresectable Advanced Esophagogastric Junction Carcinoma with Multiple Liver Metastases after Successful Second-Line Treatment with Nab-Paclitaxel and Ramucirumab Following a Refractory Response to S-1 plus CDDP Therapy-A Case Report].
Fujita T; Shimizu Y; Dongping F; Yamamoto N; Kobayashi M; Iwabu H; Tsuji A
Gan To Kagaku Ryoho; 2020 Nov; 47(11):1597-1600. PubMed ID: 33268735
[TBL] [Abstract][Full Text] [Related]
20. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Wilke H; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov O; Kim TY; Cunningham D; Rougier P; Komatsu Y; Ajani J; Emig M; Carlesi R; Ferry D; Chandrawansa K; Schwartz JD; Ohtsu A;
Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
